Scarica l'app Stockscreener
4.5141
0.33%
0.0141
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Maxcyte Inc Borsa (MXCT) Ultime notizie
MaxCyte® Acquires SeQure Dx To Broaden Cell Engineering Offerings With On-Target and Off-Target Editing Assessments - Technology Networks
MaxCyte Expands Stock Capital with New Common Stock Issuance - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Shares Purchased by Gagnon Securities LLC - MarketBeat
MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 Shares - MarketBeat
ConnectOne Bancorp (CNOB) Issues Press Release on Acquisition of SeQure Dx by MaxCyte - Defense World
MaxCyte, Inc. Acquires SeQure DX Inc. to Enhance Cell Engineering Offerings - Defense World
MaxCyte director exercises options, sells shares - Investing.com
MaxCyte Announces Executive Stock Transaction - TipRanks
MaxCyte director exercises options, sells shares By Investing.com - Investing.com Canada
MaxCyte Acquires SeQure Dx - FinSMEs
MaxCyte Buys SeQure Dx for Up to $7M - USA Herald
MaxCyte announces acquisition of SeQure Dx - ShareCast
Market news - Research the market
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT) -January 30, 2025 at 10:37 am EST - Marketscreener.com
Cell Engineering Biz MaxCyte Buys Gene Firm For Up To $7M - Law360
MaxCyte buys gene therapy analytics firm SeQure Dx -January 30, 2025 at 08:56 am EST - Marketscreener.com
MaxCyte acquires SeQure Dx for $4.5M at closing, sees accretion - TipRanks
Cell Engineering Group MaxCyte Buys US-based SeQure Dx -January 30, 2025 at 05:05 am EST - Marketscreener.com
MaxCyte Acquires Gene Editing Analytics Company SeQure Dx -January 30, 2025 at 04:25 am EST - Marketscreener.com
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments - The Manila Times
MaxCyte Expands Cell Engineering Capabilities with Acquisition of SeQure Dx - TipRanks
MaxCyte's Strategic Move: $7M Deal Transforms Gene Therapy Safety Testing Landscape - StockTitan
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics - MSN
BlackRock Increases Stake in MaxCyte, Inc. - TipRanks
Investors push MaxCyte (LON:MXCT) 9.7% lower this week, company's increasing losses might be to blame - Yahoo Finance
Should You Investigate MaxCyte, Inc. (LON:MXCT) At UK£3.65? - Simply Wall St
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MSN
JPMorgan Chase & Co. Decreases Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte (NASDAQ:MXCT) Stock Price Down 5.8%Here's What Happened - MarketBeat
How to interpret MaxCyte Inc (MXCT)’s stock chart patterns - US Post News
Vertex Pharmaceutic (VRTX-Q) QuotePress Release - The Globe and Mail
MaxCyte Sees Increase in BlackRock Holdings - TipRanks
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why - Yahoo Finance
BlackRock Increases Stake in MaxCyte to 7.57% - TipRanks
MaxCyte (NASDAQ: MXCT) Announces Preliminary Financial Results for Q4 and FY 2024ROCKVILLE, MD, January 13, 2025 — MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a prominent cell-engineering company specializing in platform technologies for adv - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Stake Boosted by Barclays PLC - Defense World
Barclays PLC Has $645,000 Position in MaxCyte, Inc. (NASDAQ:MXCT) - MarketBeat
All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy - MSN
What Is MaxCyte, Inc.'s (LON:MXCT) Share Price Doing? - Yahoo Finance
Maxcyte general counsel sells shares worth $20,271 By Investing.com - Investing.com Nigeria
MaxCyte estimates higher Q4 core revenue from last year - MSN
David I. Sandoval Sells 4,466 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock - MarketBeat
Maxcyte general counsel sells shares worth $20,271 - Investing.com
MaxCyte expects growth in core revenue for Q4 and full year 2024 - Investing.com Canada
MaxCyte (NASDAQ:MXCT) Shares Up 8.2%Here's Why - MarketBeat
MaxCyte expects growth in core revenue for Q4 and full year 2024 By Investing.com - Investing.com South Africa
0.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):